Wide Ranks

AVTE

Aerovate Therapeutics, Inc.

2.64

Top Statistics
Market Cap 76 M Forward PE -5.68 Revenue Growth 0.00 %
Current Ratio 8.78 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.1330 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 88 M Total Cash Per Share 3.07 Total Debt 540000
Total Debt To Equity 0.6710 Current Ratio 8.78 Book Value Per Share 2.79
All Measures
Short Ratio 111.00 % Message Board Id finmb_650355034 Shares Short Prior Month 664994
Return On Equity -0.8206 City Waltham Uuid cbf275de-3fc7-3baa-b402-2df34de7643f
Previous Close 2.68 First Trade Date Epoch Utc 1 B Book Value 2.79
Total Debt 540000 Volume 213471 Price To Book 0.9469
Fifty Two Week Low 1.25 Total Cash Per Share 3.07 Shares Short Previous Month Date 1 B
Target Median Price 2.00 Audit Risk 7 Max Age 86400
Sand P52 Week Change 0.3133 Target Mean Price 2.33 Net Income To Common -84611000
Short Percent Of Float 0.1668 Implied Shares Outstanding 28 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 302640 Average Volume10days 302640
Total Cash 88 M Next Fiscal Year End 1 B Held Percent Insiders 0.0002
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 8 Regular Market Previous Close 2.68 Target Low Price 2.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.33 Open 2.70
Free Cashflow -48156876 State MA Dividend Yield 0.00 %
Return On Assets -0.4867 Time Zone Short Name EST Board Risk 7
Trailing Eps -2.99 Day Low 2.62 Address1 930 Winter Street
Shares Outstanding 28 M Compensation Risk 9 Price Hint 4
Target High Price 3.00 Website https://aerovatetx.com 52 Week Change -0.8320
Average Volume 781525 Forward Eps -1.00 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 860.20 % Is_sp_500 False
Regular Market Day High 2.70 Profit Margins 0.00 % Debt To Equity 0.6710
Fifty Two Week High 32.41 Day High 2.70 Shares Short 1 M
Regular Market Open 2.70 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0655 Operating Cashflow -74949000
Currency USD Time Zone Full Name America/New_York Market Cap 76 M
Is_nasdaq_100 False Zip 02451 Quote Type EQUITY
Industry Biotechnology Long Name Aerovate Therapeutics, Inc. Overall Risk 8
Regular Market Day Low 2.62 Held Percent Institutions 1.02 Current Price 2.64
Address2 Suite M-500 Enterprise To Ebitda 0.1330 Financial Currency USD
Current Ratio 8.78 Industry Disp Biotechnology Number Of Analyst Opinions 3
Country United States Float Shares 11 M Two Hundred Day Average 10.76
Governance Epoch Date 1 B Enterprise Value -11979243 Forward PE -5.68
Regular Market Volume 213471 Ebitda -89957000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States.

It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.

The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.